Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - VIVUS, Inc. (NasdaqNM:VVUS)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Financials | Reports
Location
1172 Castro Street
Mountain View, CA 94040
Phone: (650) 934-5200
Fax: (650) 934-5379
Email: webmaster@vivus.com
Employees (last reported count): 133
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 8%
·Over the last 6 months:
 · 3 insider sells; 5,000  shares
  (0.2% of insider shares)
·Institutional: 24% (26% of float)
(77 institutions)
·Net Inst. Buying: 566.0K shares (+6.69%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
VIVUS, Inc. is a pharmaceutical company engaged in developing, acquiring and marketing products to improve quality-of-life disorders in men and women, with a focus on sexual dysfunction. The Company developed and markets in the United States, Muse (alprostadil) and Actis, two treatments of erectile dysfunction (ED). VIVUS has ongoing research and development programs in male ED, female sexual dysfunction (FSD) and male premature ejaculation. Adding to the Company's research and development pipeline in the first quarter of 2001, VIVUS licensed from Tanabe Seiyaku Co., Ltd., the proprietary phosphodiesterase type five inhibitor compound, TA-1790, for the oral and local treatment of male and female sexual dysfunction. In January 2001, the Company began enrolling patients in a multi-center clinical study for its FSD product, Alista, intended to evaluate the sexual response in women with a primary diagnosis of Female Sexual Arousal Disorder.
More from Market Guide: Expanded Business Description

Financial Summary
VIVUS, Inc. focuses on the design and development of products for the treatment of erectile dysfunction whose products include MUSE (alprostadil) and ACTIS. For the six months ended 6/30/01, sales decreased 10% to $12.7 million. Net loss totaled $5.8 million vs. an income of $2.4 million. Revenues reflect lower MUSE prescriptions and termination of the Company's distribution agreement with AstraZeneca. Net loss reflects a $5 million payment for the licensing of the TA-1790 compound.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Pay

Virgil Place, M.D., 76
Chairman and CSO
--  
Leland Wilson, 56
Pres, CEO
$378K
Richard Walliser, 57
CFO, VP-Fin.
171K
Neil Gesundheit, M.D., 48
VP- Clinical Research and CMO
--  
Carol Karp, 48
VP- Regulatory Affairs and Project Management
185K
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:VVUSAs of 31-Aug-2001
Price and Volume
52-Week Low
on 21-Dec-2000
$1.594
Recent Price$4.00 
52-Week High
on 21-Sep-2000
$5.625
Beta1.77 
Daily Volume (3-month avg)98.5K
Daily Volume (10-day avg)112.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-20.0%
52-Week Change
relative to S&P500
+7.3%
Share-Related Items
Market Capitalization$130.4M
Shares Outstanding32.6M
Float30.0M
Dividends & Splits
Annual Dividendnone 
Last Split: 2 for 1 on 24-June-1997
Per-Share Data
Book Value (mrq)$1.37 
Earnings (ttm)-$0.02 
Earnings (mrq)-$0.03 
Sales (ttm)$0.76 
Cash (mrq)$0.89 
Valuation Ratios
Price/Book (mrq)2.91 
Price/EarningsN/A 
Price/Sales (ttm)5.25 
Income Statements
Sales (ttm)$25.0M
EBITDA (ttm)-$178.0K
Income available to common (ttm)-$543.0K
Profitability
Profit Margin (ttm)-2.2%
Operating Margin (ttm)-9.9%
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-0.83%
Return on Equity (ttm)-1.18%
Financial Strength
Current Ratio (mrq)2.76 
Debt/Equity (mrq)0 
Total Cash (mrq)$29.1M
Short Interest
As of 8-Aug-2001
Shares Short1.44M
Percent of Float4.8%
Shares Short
(Prior Month)
1.53M
Short Ratio19.93 
Daily Volume72.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.